NEW YORK (GenomeWeb News) – Sequenom today said that it has inked a contract with sales and marketing services firm PDI to provide the sales force that will launch and commercialize the firm's SEQureDx non-invasive prenatal genetic screening tests.

PDI will work with the Sequenom Center for Molecular Medicine, the clinical lab subsidiary of Sequenom, in supporting commercialization of the firm's Rhesus D genotyping test, its Down syndrome test, and other laboratory-developed tests. The partners will hire, train, and develop a sales team for the SCMM.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: mouse genome functional analysis, more sensitive chromatin immunoprecipitation, and more.

The Center for Data Innovation and HealthITNow argue for re-building of genomic research infrastructure.

A Senate committee has unanimously approved a bill to require articles resulting from federally funded projects to be made publicly available, according to ScienceInsider.

The US is heading toward another budget showdown, Nature News says.